| British Columbia, Canada                                                               |   | 980597776                                 |
|----------------------------------------------------------------------------------------|--------|-------------------------------------------|
| (State or Other Jurisdiction ofIncorporation or Organization)                          |   | (I.R.S. EmployerIdentification No.)       |
|                                                                                   |   |                                      |
|                                                                                   |   |                                      |
| 100-8900 Glenlyon Parkway, Burnaby, BC V5J 5J8(Address of Principal Executive Offices) |
|                                                                                   |   |                                      |
|                                                                                   |   |                                      |
| 604-419-3200 (Registrant’s Telephone Number, Including Area Code):          |
|                                                                                   |
| Securities registered pursuant to Section 12(b) of the Act:                            |
|                                                                                   |   |                                      |
| Title of Each Class                                                                    |   | Name of Each Exchange on Which Registered |
| Common shares, without par value                                                       |   | The NASDAQ Stock Market LLC               |
|                                                                                   |   |                                      |
| Securities registered pursuant to Section 12(g) of the Act:                            |

----

| Large accelerated filer o | Accelerated filer ý                      | Non-accelerated filer o | Smaller reporting company o |
|---------------------------|-----------------------------------------------|-------------------------|-----------------------------|
|                      | (Do not check if a smaller reporting company) |

----

----

|     |                                                                                           | Page   |
|----------|------------------------------------------------------------------------------------------------|--------|
|     |                                                                                           |   |
|     |                                                                                           |   |
| PART III | 3                                                                                              |
|     |                                                                                           |
| Item 10. | Directors, Executive Officers and Corporate Governance                                         | 3      |
| Item 11. | Executive Compensation                                                                         | 8      |
| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters | 19     |
| Item 13. | Certain Relationships and Related Transactions, and Director Independence                      | 20     |
| Item 14. | Principal Accountant Fees and Services                                                         | 20     |
|     |                                                                                           |   |
| PART IV  | 21                                                                                             |
|     |                                                                                           |
| Item 15. | Exhibits and Financial Statement Schedules                                                     | 21     |

----

PART III

| Item 10. | Directors, Executive Officers and Corporate Governance |
|----------|--------------------------------------------------------|

| Name                       |   | Age |   | Position(s)                            |
|----------------------------|--------|-----|--------|----------------------------------------|
| Mark Murray*               |   | 66  |   | Chief Executive Officer, and Director  |
| Bruce Cousins              |   | 54  |   | Chief Financial Officer                |
| Mark Kowalski              |   | 60  |   | Chief Medical Officer                  |
| Patrick Higgins            |   | 57  |   | Chief Operating Officer                |
| Michael Sofia              |   | 56  |   | Chief Scientific Officer               |
| Michael Abrams             |   | 58  |   | Chief Discovery Officer                |
| Vivek Ramaswamy*†    |   | 29  |   | Chairman of the Board                  |
| Herbert Conrad*+^†   |   | 82  |   | Director                               |
| Richard Henriques*+† |   | 59  |   | Director                               |
| Frank Karbe*+^             |   | 47  |   | Director                               |
| Keith Manchester*^         |   | 46  |   | Director                               |
| William Symonds*           |   | 47  |   | Chief Development Officer and Director |

| * | Nominee for election to Board |
|---|-------------------------------|

| + | Member of the Audit Committee |
|---|-------------------------------|

| ^ | Member of the Nominating and Governance Committee |
|---|---------------------------------------------------|

| † | Member of the Executive Compensation and Human Resources Committee |
|---------|--------------------------------------------------------------------|

----

----

|   | · | overseeing the work of the auditors engaged for the purpose of preparing or issuing an auditor’s report or performing other audit, review or attest services for the Company; |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | evaluating the performance, and assessing the qualifications, of our auditor and recommending to our Board of Directors the appointment of, and compensation for, our auditor for the purpose of preparing or issuing an auditor report or performing other audit, review or attest services; |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | subject to the appointment of our auditor in accordance with applicable corporate formalities, determining and approving the engagement of, and compensation to be paid to, our auditor; |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | determining and approving the engagement, prior to the commencement of such engagement, of, and compensation for, our auditor and to perform any proposed permissible non-audit services; |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | reviewing our financial statements and management’s discussion and analysis of financial condition and results of operations and recommending to our Board of Directors whether or not such financial statements and management’s discussion and analysis of financial condition and results of operations should be approved by our Board of Directors; |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | conferring with our auditor and with our management regarding the scope, adequacy and effectiveness of internal financial reporting controls in effect; |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | establishing procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls or auditing matters and the confidential and anonymous submission by our employees of concerns regarding questionable accounting or auditing matters; and |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | reviewing and discussing with our management and auditor, as appropriate, our guidelines and policies with respect to risk assessment and risk management, including our major financial risk exposures and investment and hedging policies and the steps taken by our management to monitor and control these exposures. |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | reviewing and making recommendations to our Board of Directors for our chief executive officer and other executive officers: annual base salary; annual incentive bonus, including the specific goals and amount; equity compensation; employment agreements, severance arrangements and change in control agreements/provisions; and any other benefits, compensations, compensation policies or arrangements; |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | reviewing and making recommendations to our Board of Directors regarding our overall compensation plans and structure, including incentive compensation and equity based plans; |
|--------|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | reviewing and making recommendations to our Board of Directors regarding the compensation to be paid to our non-employee directors, including any retainer, committee and committee chair fees and/or equity compensation; |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | reviewing any report to be included in our periodic filings or proxy statement/circular; and |
|--------|--------|----------------------------------------------------------------------------------------------|

|   | · | acting as administrator of our equity compensation plans. |
|--------|--------|-----------------------------------------------------------|

|   | · | establishing criteria for Board membership and identifying, evaluating, reviewing and recommending qualified candidates to serve on the Board; |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | evaluating, reviewing and considering the recommendation for nomination of incumbent directors for re-election to the Board; |
|--------|--------|------------------------------------------------------------------------------------------------------------------------------|

|   | · | periodically reviewing and assessing the performance of our Board, including Board committees; |
|--------|--------|------------------------------------------------------------------------------------------------|

|   | · | developing and reviewing a set of corporate governance principles for Tekmira. |
|--------|--------|--------------------------------------------------------------------------------|

----

----

| Item 11. | Executive Compensation |
|----------|------------------------|

| Name and principal position        | Year   |   | Salary(US$) |    |   | Salary(C$) |   |    | Options(US$) (1) |   |    | Annualincentivecashbonus(US$) |   |   | All othercompensation(US$) (2) |    |   | Totalcompensation(US$) |   |
|------------------------------------|--------|--------|-------------|---------|--------|------------|--------|---------|------------------|--------|---------|-------------------------------|--------|--------|--------------------------------|---------|--------|------------------------|--------|
| Dr. Mark Murray                    | 2014   |   |        | 400,000 |   |       | NA     |    |             |   | 466,404 |                          |   |   | 180,000                        |    |   |                   | 38,848 |   |   |   | 1,085,252 |   |
| President and                      | 2013   |   |        | 377,500 |   |       | NA     |    |             |   | -       |                          |   |   | 160,359                        |    |   |                   | 43,792 |   |   |   | 581,651 |   |
| Chief Executive Officer            | 2012   |   |        | 350,000 |   |       | NA     |    |             |   | 165,768 |                          |   |   | 347,984                        |    |   |                   | 62,040 |   |   |   | 925,792 |   |
|                               |   |   |        |    |   |       |   |    |             |   |    |                          |   |   |                           |    |   |                   |   |   |   |   |   |   |
| Mr. Bruce Cousins (3)              | 2014   |   |        | 276,117 |   |       |   | 305,000 |             |   |    | -                             |   |   |                           | 99,583  |   |                   |   | 44,026 |   |   |   | 419,725 |   |
| Executive Vice President, Finance  | 2013   |   |        | 69,480  |   |       |   | 71,558  |             |   |    | 1,247,159                     |   |   |                           | 24,318  |   |                   |   | 2,085 |   |   |   | 1,343,040 |   |
| and Chief Financial Officer        | 2012   |   |        | -       |   |       |   | -       |             |   |    | -                             |   |   |                           | -       |   |                   |   | - |   |   |   | - |   |
|                               |   |   |        |    |   |       |   |    |             |   |    |                          |   |   |                           |    |   |                   |   |   |   |   |   |   |   |
| Dr. Ian MacLachlan                 | 2014   |   |        | 292,299 |   |       |   | 322,875 |             |   |    | 333,146                       |   |   |                           | -       |   |                   |   | 15,088 |   |   |   | 640,532 |   |
| Former Executive Vice President    | 2013   |   |        | 305,851 |   |       |   | 315,000 |             |   |    | -                             |   |   |                           | 113,739 |   |                   |   | 9,422 |   |   |   | 429,011 |   |
| and Former Chief Technical Officer | 2012   |   |        | 295,190 |   |       |   | 295,000 |             |   |    | 118,405                       |   |   |                           | 295,190 |   |                   |   | 8,856 |   |   |   | 717,642 |   |
|                               |   |   |        |    |   |       |   |    |             |   |    |                          |   |   |                           |    |   |                   |   |   |   |   |   |   |   |
| Dr. Mark Kowalski (5)              | 2014   |   |        | 333,125 |   |       | NA     |    |             |   | 333,146 |                          |   |   | 105,000                        |    |   |                   | 15,986 |   |   |   | 787,257 |   |
| Senior Vice President              | 2013   |   |        | 128,623 |   |       | NA     |    |             |   | 261,819 |                          |   |   | 36,240                         |    |   |                   | 3,859  |   |   |   | 430,541 |   |
| and Chief Medical Officer          | 2012   |   |        | -       |   |       |   | -       |             |   |    | -                             |   |   |                           | -       |   |                   |   | - |   |   |   | - |   |
|                               |   |   |        |    |   |       |   |    |             |   |    |                          |   |   |                           |    |   |                   |   |   |   |   |   |   |   |
| Dr. Mike Abrams (6)                | 2014   |   |        | 243,758 |   |       |   | 270,000 |             |   |    | 529,515                       |   |   |                           | 87,995  |   |                   |   | 8,462 |   |   |   | 869,760 |   |
| Executive Vice President           | 2013   |   |        | -       |   |       |   | -       |             |   |    | -                             |   |   |                           | -       |   |                   |   | - |   |   |   | - |   |
| and Chief Discovery Officer        | 2012   |   |        | -       |   |       |   | -       |             |   |    | -                             |   |   |                           | -       |   |                   |   | - |   |   |   | - |   |

| 1.   | The fair value of each option is estimated as at the date of grant using the most widely accepted option pricing model, Black-Scholes. The fair value of options computed on the grant date is in accordance with FASB ASC Topic 718. The weighted average option pricing assumptions and the resultant fair values for options awarded to Named Executive Officers in 2012 are as follows: expected average option term of ten years; a zero dividend yield; a weighted average expected volatility of 121.5%; and, a weighted average risk-free interest rate of 1.46%. The weighted average option pricing assumptions and the resultant fair values for options awarded to Named Executive Officers for fiscal 2013 are as follows: expected average option term of ten years; a zero dividend yield; a weighted average expected volatility of 114.7%; and, a weighted average risk-free interest rate of 2.49%. The weighted average option pricing assumptions and the resultant fair values for options awarded to Named Executive Officers for fiscal 2014 are as follows: expected average option term of ten years; a zero dividend yield; a weighted average expected volatility of 105.0%; and, a weighted average risk-free interest rate of 2.49%. Options awarded to the Named Executive Officers in February 2015 are not included in the above table. |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.   | All other compensation in 2012, 2013 and 2014 includes Registered Retirement Savings Plan, or RRSP, or equivalent matching payments of 3% of salary. In 2012, 2013 and 2014 all of our full-time employees and executives were eligible for RRSP or equivalent matching payments. Dr. Murray’s and Dr. Kowalski’s other compensation also includes reimbursement of personal tax filing service fees up to a maximum of $10,000 and $5,000 per year, respectively. Dr. Murray’s and Dr. MacLachlan’s other compensation also includes amounts claimed under their contractual entitlement to reimbursement of any health expenses incurred, including their families’ health expenses, that are not covered by insurance. Mr. Cousins’ other compensation also includes amounts for housing provided. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.    | Mr. Cousins commenced employment with Tekmira in October 2013 with an annual salary of $286,762 (C$305,000) and was granted 150,000 new hire stock options at that time. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.   | Dr. MacLachlan terminated his employment as Chief Technical Officer pursuant to the “good reason” termination provision in his Employment Agreement, effective December 31, 2014 and received a total severance payment of $1,084,563 (C$1,258,201). |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.   | Dr. Kowalski commenced employment in August 2013 with an annual salary of $325,000 and was granted 50,000 new hire stock options at that time. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 6.   | Dr. Abrams commenced employment in January 2014 with an annual salary of $243,758 (C$270,000) and was granted 75,000 new hire stock options at that time. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • | to recruit and subsequently retain highly qualified executive officers by offering overall compensation which is competitive with that offered for comparable positions in other biotechnology companies; |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | • | to motivate executives to achieve important corporate performance objectives and reward them when such objectives are met; and |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------|

|   | • | to align the interests of executive officers with the long-term interests of shareholders through participation in our stock-based compensation plan (the “2011 Plan”). |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Provision of Services |
|--------|--------|-----------------------|

|   | · | Fees received as a percentage of total revenue |
|--------|--------|------------------------------------------------|

|   | · | Policies and Procedures that are intended to prevent conflicts of interest |
|--------|--------|----------------------------------------------------------------------------|

|   | · | Business or personal relationships with members of the Committee |
|--------|--------|------------------------------------------------------------------|

|   | · | Business or personal relationships with executive officers of the Company |
|--------|--------|---------------------------------------------------------------------------|

|   | · | Stock owned |
|--------|--------|-------------|

| Achillion Pharmaceuticals Inc | Neuralstem Inc                |
|-------------------------------|-------------------------------|
| Agenus Inc                    | Omeros Corp                   |
| Amicus Therapeutics Inc       | Oncothyreon Inc               |
| Arrowhead Research Corp       | Orexigen Therapeutics Inc     |
| Biocryst Pharmaceuticals Inc  | Regulus Therapeutics Inc      |
| Celldex Therapeutics Inc      | Repros Therapeutics Inc       |
| Corcept Therapeutics          | Rexahn Pharmaceuticals Inc    |
| Cytokinetics Inc              | Sangamo Biosciences Inc       |
| Dicerna Pharmaceuticals, Inc. | Sarepta Therapeutics Inc      |
| Galena Biopharma Inc          | Sunesis Pharmaceuticals Inc   |
| Geron Corp                    | Synta Pharmaceuticals         |
| Idera Pharmaceuticals Inc     | Targacept Inc                 |
| Inovio Pharmaceuticals Inc    | Threshold Pharmaceuticals Inc |
| Insmed Inc                    | Ziopharm Oncology Inc         |

----

----

----

| Dr. Mark Murray    | 43.8% |
|--------------------|-------|
| Mr. Bruce Cousins  | 35.0% |
| Dr. Ian MacLachlan | 37.2% |
| Dr. Mark Kowalski  | 30.6% |

| Dr. Mark Murray     | 45.0%                                                 |
|---------------------|-------------------------------------------------------|
| Mr. Bruce Cousins   | 36.0%         |
| Dr. Ian MacLachlan* |                                                  |
| Dr. Mark Kowalski   | 31.5%                                                 |
| Dr. Abrams          | 36.0%                                                 |

----

----

|                                                 |              |   | Estimated Possible Payouts Under Non-Equity Incentive Plan Awards(2) |   |   | Stock Awards: Number of |   |   | Option Awards: Number of Securities |   |   | Exercise or Base Price of |   |   | Grant Date Fair Value of Stock and Option |   |
|------------------------------------------------------|-------------------|--------|----------------------------------------------------------------------|--------|--------|-------------------------|--------|--------|-------------------------------------|--------|--------|---------------------------|--------|--------|-------------------------------------------|--------|
| Name                                                 | Date of Grant (1) |   | Threshold ($)                                                        |   |   | Target ($)              |   |   | Maximum ($)                         |   |   | Shares ofStock(3)         |   |   | Underlying Options                        |   |   | OptionAwards ($) |   |   | Awards($)(4) |   |
| Mark Murray, Ph.D.                                   | 2/5/14            |   | $                                                                    | -      |   |                    | $      | -      |                                |   | $      | -                         |   |   |                                      | -      |   |   |   | 35,000 |   |   | $ | 14.85 |   |   | $ | 466,404 |   |
| President and Chief Executive Officer                |              |   |                                                                 |   |   |                    |   |   |                                |   |   |                      |   |   |                                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Bruce Cousins                                        | N/A               |   | $                                                                    | -      |   |                    | $      | -      |                                |   | $      | -                         |   |   |                                      | -      |   |   |   | N/A |   |   |   | N/A |   |   | $ | - |   |
| Executive Vice President and Chief Financial Officer |              |   |                                                                 |   |   |                    |   |   |                                |   |   |                      |   |   |                                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Ian MacLachlan, Ph.D.                                | 2/5/14            |   | $                                                                    | -      |   |                    | $      | -      |                                |   | $      | -                         |   |   |                                      | -      |   |   |   | 25,000 |   |   | $ | 14.85 |   |   | $ | 333,146 |   |
| Executive Vice President and Chief Medical Officer   |              |   |                                                                 |   |   |                    |   |   |                                |   |   |                      |   |   |                                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Mike Abrams, Ph.D.                                   | 1/2/14            |   | $                                                                    | -      |   |                    | $      | -      |                                |   | $      | -                         |   |   |                                      | -      |   |   |   | 75,000 |   |   | $ | 14.85 |   |   | $ | 529,515 |   |
| Executive Vice President and Chief Discovery Officer |              |   |                                                                 |   |   |                    |   |   |                                |   |   |                      |   |   |                                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Mark Kowalski, M.D., Ph.D.                           | 2/5/14            |   | $                                                                    | -      |   |                    | $      | -      |                                |   | $      | -                         |   |   |                                      | -      |   |   |   | 25,000 |   |   | $ | 14.85 |   |   | $ | 333,146 |   |
| Senior Vice President and Chief Medical Officer      |              |   |                                                                 |   |   |                    |   |   |                                |   |   |                      |   |   |                                      |   |   |   |   |   |   |   |   |   |   |   |   |   |   |

| 1.   | The stock option awards reported in the 2014 Grants of Plan-Based Awards Table were granted as 2013 annual stock option awards for Dr. Murray, Dr. MacLachlan, and Dr. Kowalski. The stock option awards granted in 2014 to Dr. Abrams relate to the commencement of his employment in January 2014. |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 2.   | We do not have any non-equity incentive plans. A discretionary annual incentive cash bonus may be included as a component of our executive compensation package – see Item 11 subsection “Elements of Executive Compensation”. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.   | Our 2011 Plan allows for the issuance of tandem stock appreciation rights, restricted stock units and deferred stock units, but we have not granted any stock awards of this kind to date. |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.   | The Grant Date Fair Value, computed in accordance with FASB ASC Topic 718, represents the value of stock options granted during the year. The amounts reported in the Grants of Plan-Based Awards Table reflect our accounting expense and may not represent the amounts our named executive officers will actually realize from the awards. Whether, and to what extent, a named executive officer realizes value will depend on our actual operating performance, stock price fluctuations and that named executive officer’s continued employment. Our Designated Plans, governed substantially under the same terms as our 2011 Plan, provide that the option exercise price is always at least equal to the closing market price of the common shares on the day preceding the date of grant and the term may not exceed 10 years. These stock options vest one quarter immediately, and one quarter on the next three anniversaries of their grant date. As the closing market price of the common shares is denominated in Canadian dollars, the Exercise Prices shown in the table have been translated to US dollars using the last closing rate for the year, and the Grant Date Fair Value shown in the table have been translated to US dollars using the average exchange rate for the year. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|                  | Option-based awards - total outstanding options (1)   |
|-----------------------|-------------------------------------------------------|
| Name                  | Number of securitiesunderlying unexercisedoptions (#) | Optionexercise price(C$) | Optionexercise price(US$) | Option grant date (2) | Value ofunexercisedin-the-moneyoptions (3)(C$) | Value ofunexercisedin-the-moneyoptions (4)(US$) |
| Dr. Mark Murray (5)   | 219,428                                               | 0.44 | 0.44 | September 13, 2005 |   3,802,687 |       3,433,430 |
|                  | 27,007                                                | 0.44 | 0.44 | March 2, 2008 |      468,031 |          422,583 |
|                  | 30,000                                                | 4.65 | 4.01 | August 31, 2008 |     393,600 |          339,283 |
|                  | 25,000                                                | 1.80 | 1.55 | December 9, 2008 |     399,250 |          344,154 |
|                  | 25,000                                                | 3.85 | 3.32 | January 28, 2010 |     348,000 |          299,976 |
|                  | 35,000                                                | 2.40 | 2.07 | August 10, 2011 |     537,950 |          463,713 |
|                  | 35,000                                                | 1.70 | 1.47 | December 23, 2011 |     562,450 |          484,832 |
|                  | 35,000                                                | 5.15 | 4.44 | December 10, 2012 |     441,700 |          380,745 |
|                  | 35,000                                                | 16.40 | 14.14 | February 5, 2014 |       47,950 |           41,333 |
| Mr. Bruce Cousins     | 150,000                                               | 9.12 | 7.86 | October 7, 2013 |  1,297,500 | 1,118,445 |
| Dr. Ian MacLachlan(6) | 30,000                                                | 4.65 | 4.01 | August 31, 2008 |     393,600 |          339,283 |
|                  | 16,000                                                | 1.80 | 1.55 | December 9, 2008 |     255,520 |          220,258 |
|                  | 16,000                                                | 3.85 | 3.32 | January 28, 2010 |     222,720 |          191,985 |
|                  | 25,000                                                | 2.40 | 2.07 | August 10, 2011 |     384,250 |          331,224 |
|                  | 25,000                                                | 1.70 | 1.47 | December 23, 2011 |     401,750 |          346,309 |
|                  | 25,000                                                | 5.15 | 4.44 | December 10, 2012 |     315,500 |          271,961 |
|                  | 25,000                                                | 16.40 | 14.14 | February 5, 2014 |       34,250 |           29,523 |
| Dr. Mark Kowalski     | 50,000                                                | 5.75 | 4.96 | August 12, 2013 |     601,000 |          518,062 |
|                  | 25,000                                                | 16.40 | 14.14 | February 5, 2014 |       34,250 |           29,523 |
| Dr. Mike Abrams(7)    | 17,044                                                | 0.44 |               0.44 | September 13, 2005 |          295,373 |          266,691 |
|                  | 5,445                                                 | 0.44 |               0.44 | January 1, 2006 |            94,362 |            85,199 |
|                  | 675                                                   | 0.44 |               0.44 | April 4, 2007 |            11,698 |            10,562 |
|                  | 13,503                                                | 0.44 |               0.44 | May 28, 2007 |          234,007 |          211,284 |
|                  | 5,000                                                 | 1.80 | 1.55 | December 9, 2008 |            79,850 |            68,831 |
|                  | 5,000                                                 | 3.85 | 3.32 | January 28, 2010 |            69,600 |            59,995 |
|                  | 5,000                                                 | 2.40 | 2.07 | August 10, 2011 |            76,850 |            66,245 |
|                  | 5,000                                                 | 1.70 | 1.47 | December 23, 2011 |            80,350 |            69,262 |
|                  | 5,000                                                 | 5.15 | 4.44 | December 10, 2012 |            63,100 |            54,392 |
|                  | 75,000                                                | 8.30 | 7.15 | January 2, 2014 |          710,250 |          612,236 |

----

|                  | Option-based awards - outstanding vested options (1)         |
|-----------------------|--------------------------------------------------------------|
| Name                  | Number of securitiesunderlying unexercisedvested options (#) | Optionexercise price(C$) | Optionexercise price(US$) | Option grant date (2) | Value ofunexercisedin-the-moneyoptions (3)(C$) | Value ofunexercisedin-the-moneyoptions (4)(US$) |
| Dr. Mark Murray (5)   | 219,428                                                      | 0.44 | 0.44 | September 13, 2005 |   3,802,687 |       3,433,430 |
|                  | 27,007                                                       | 0.44 | 0.44 | March 2, 2008 |      468,031 |          422,583 |
|                  | 30,000                                                       | 4.65 | 4.01 | August 31, 2008 |     393,600 |          339,283 |
|                  | 25,000                                                       | 1.80 | 1.55 | December 9, 2008 |     399,250 |          344,154 |
|                  | 25,000                                                       | 3.85 | 3.32 | January 28, 2010 |     348,000 |          299,976 |
|                  | 35,000                                                       | 2.40 | 2.07 | August 10, 2011 |     537,950 |          463,713 |
|                  | 35,000                                                       | 1.70 | 1.47 | December 23, 2011 |     562,450 |          484,832 |
|                  | 26,250                                                       | 5.15 | 4.44 | December 10, 2012 |     331,275 |          285,559 |
|                  | 8,750                                                        | 16.40 | 14.14 | February 5, 2014 |       11,988 |           10,333 |
| Mr. Bruce Cousins     | 75,000                                                       | 9.12 | 7.86 | October 7, 2013 |     648,750 | 559,223 |
| Dr. Ian MacLachlan(6) | 30,000                                                       | 4.65 | 4.01 | August 31, 2008 |     393,600 |          339,283 |
|                  | 16,000                                                       | 1.80 | 1.55 | December 9, 2008 |     255,520 |          220,258 |
|                  | 16,000                                                       | 3.85 | 3.32 | January 28, 2010 |     222,720 |          191,985 |
|                  | 25,000                                                       | 2.40 | 2.07 | August 10, 2011 |     384,250 |          331,224 |
|                  | 25,000                                                       | 1.70 | 1.47 | December 23, 2011 |     401,750 |          346,309 |
|                  | 25,000                                                       | 5.15 | 4.44 | December 10, 2012 |     315,500 |          271,691 |
|                  | 25,000                                                       | 16.40 | 14.14 | February 5, 2014 |        34,250 |            29,523 |
| Dr. Mark Kowalski     | 25,000                                                       | 5.75 | 4.96 | August 12, 2013 |     300,500 |          259,031 |
|                  | 6,250                                                        | 16.40 | 14.14 | February 5, 2014 |         8,563 |             7,381 |
| Dr. Mike Abrams(7)    | 17,044                                                       | 0.44 | 0.44 | September 13, 2005 |          295,373 |          266,691 |
|                  | 5,445                                                        | 0.44 | 0.44 | January 1, 2006 |            94,362 |            85,199 |
|                  | 675                                                          | 0.44 | 0.44 | April 4, 2007 |            11,698 |            10,562 |
|                  | 13,503                                                       | 0.44 | 0.44 | May 28, 2007 |          234,007 |          211,284 |
|                  | 5,000                                                        | 1.80 | 1.55 | December 9, 2008 |            79,850 |            68,831 |
|                  | 5,000                                                        | 3.85 | 3.32 | January 28, 2010 |            69,600 |            59,995 |
|                  | 5,000                                                        | 2.40 | 2.07 | August 10, 2011 |            76,850 |            66,245 |
|                  | 5,000                                                        | 1.70 | 1.47 | December 23, 2011 |            80,350 |            69,262 |
|                  | 5,000                                                        | 5.15 | 4.44 | December 10, 2012 |            63,100 |            54,392 |
|                  | 18,750                                                       | 8.30 | 7.15 | January 2, 2014 |          177,563 |          153,059 |

|                | Option-based awards - outstanding unvested options (1)         |
|---------------------|----------------------------------------------------------------|
| Name                | Number of securitiesunderlying unexercisedunvested options (#) | Optionexercise price(C$) | Optionexercise price(US$) | Option grant date (2) | Value ofunexercisedin-the-moneyoptions (3)(C$) | Value ofunexercisedin-the-moneyoptions (4)(US$) |
| Dr. Mark Murray (5) | 8,750                                                          | 5.15 | 4.44 | December 10, 2012 |  110,425 |      95,186 |
|                | 26,250                                                         | 16.40 | 14.14 | February 5, 2014 |    35,963 |      31,000 |
| Mr. Bruce Cousins   | 75,000                                                         | 9.12 | 7.86 | October 7, 2013 |  648,750 | 559,223 |
| Dr. Mark Kowalski   | 25,000                                                         | 5.75 | 4.96 | August 12, 2013 |  300,500 |   259,031 |
|                | 18,750                                                         | 16.40 | 14.14 | February 5, 2014 |    25,688 |      22,143 |
| Dr. Mike Abrams(7)  | 56,250                                                         | 8.30 | 7.15 | January 2, 2014 |  532,688 | 459,177 |

----

| Name               | Option-basedawards valuevested during theyear (C$) | Option-basedawards valuevested during theyear (US$) |
|--------------------|----------------------------------------------------|-----------------------------------------------------|
| Dr. Mark Murray    | 230,475                                            | 199,858                                             |
| Mr. Bruce Cousins  | 604,875                                            | 549,192                                             |
| Dr. Ian MacLachlan | 269,188                                            | 251,890                                             |
| Dr. Mark Kowalski  | 181,250                                            | 169,735                                             |
| Dr. Mike Abrams    | -                                                  | -                                                   |

----

| Payment Type                                                                 |   | Dr. MarkMurray |      |   | Mr. BruceCousins |   |    | Dr. IanMacLachlan |   |   | Dr. MarkKowalski |   |   | Dr. Mike Abrams |    |
|------------------------------------------------------------------------------|--------|----------------|-----------|--------|------------------|--------|---------|-------------------|--------|--------|------------------|--------|--------|-----------------|---------|
| Involuntary termination by Tekmira for cause                                 |
| Cash payment                                                                 |   | $              | -         |   |             | $      | -       |              |   | $      | -                |   |   | $               | -       |   |   | $ | - |   |
| Option values (1)                                                            |   | $              | 6,083,863 |   |             | $      | 559,223 |              |   | $      | 1,730,543        |   |   | $               | 266,412 |   |   | $ | 153,059 |   |
| Benefits (2)                                                                 |   | $              | -         |   |             | $      | -       |              |   | $      | -                |   |   | $               | -       |   |   | $ | - |   |
| Involuntary termination by Tekmira upon death                                |
| Cash payment                                                                 |   | $              | -         |   |             | $      | -       |              |   | $      | -                |   |   | $               | -       |   |   | $ | - |   |
| Option values (1)                                                            |   | $              | 6,083,863 |   |             | $      | 559,223 |              |   | $      | 1,730,543        |   |   | $               | 266,412 |   |   | $ | 153,059 |   |
| Benefits (2)                                                                 |   | $              | -         |   |             | $      | -       |              |   | $      | -                |   |   | $               | -       |   |   | $ | - |   |
| Involuntary termination by Tekmira without cause                             |
| Cash payment                                                                 |   | $              | 1,108,404 |   |             | $      | 321,028 |              |   | $      | 959,319          |   |   | $               | 381,349 |   |   | $ | 315,222 |   |
| Option values (1)                                                            |   | $              | 6,210,049 |   |             | $      | 559,223 |              |   | $      | 1,730,543        |   |   | $               | 266,412 |   |   | $ | 153,059 |   |
| Benefits (2)                                                                 |   | $              | 73,980    |   |             | $      | 41,920  |              |   | $      | 125,244          |   |   | $               | 15,221  |   |   | $ | 8,057 |   |
| Involuntary termination by Tekmira without cause or                          |
|  by Executive with good reason after a change in control of the Company |
| Cash payment                                                                 |   | $              | 1,108,404 |   |             | $      | 321,028 |              |   | $      | 959,319          |   |   | $               | 381,349 |   |   | $ | 315,222 |   |
| Option values (1)                                                            |   | $              | 6,210,049 |   |             | $      | 559,223 |              |   | $      | 1,730,543        |   |   | $               | 266,412 |   |   | $ | 153,059 |   |
| Benefits (2)                                                                 |   | $              | 73,980    |   |             | $      | 41,920  |              |   | $      | 125,244          |   |   | $               | 15,221  |   |   | $ | 8,057 |   |

| (1) | This amount is based on the difference between Tekmira’s December 31, 2014 TSX closing share price of C$17.77 and the exercise price of the options that were vested as at December 31, 2014 converted into US$ at 0.8620.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2) | Ongoing benefit coverage has been estimated assuming that benefits will be payable for the full length of the severance period which would be the case if new employment was not taken up during the severance period. Benefits include extended health and dental coverage that is afforded to all of the Company’s full time employees. Dr. Murray’s benefits also include a $2,000,000 life insurance policy, the reimbursement of up to $10,000 per annum in professional fees related to the filing of his tax returns. Dr. Murray and Dr. MacLachlan’s benefits also include an estimate of the costs of reimbursement of health expenses incurred, including their families’ health expenses, that are not covered by insurance. |

| Name                                                       |   | Fees earned($) |   |   | Option-basedawards (1)($) |   |    | Total($) |   |   | Outstanding And Unexercised Options to Purchase Common Stock(#)(2) |   |
|------------------------------------------------------------|--------|---------------------|--------|--------|---------------------------|--------|---------|----------|--------|--------|--------------------------------------------------------------------|--------|
| Daniel Kisner (Board Chair) (3)                            |   |                | 81,966 |   |                      |   | 162,921 |     |   |   | 244,887                                                            |   |   | Nil |   |
| Donald Jewell (4)                                          |   |                | 57,000 |   |                      |   | 162,921 |     |   |   | 219,921                                                            |   |   | Nil |   |
| Frank Karbe (Audit Committee Chair)                        |   |                | 56,000 |   |                      |   | 162,921 |     |   |   | 218,921                                                            |   |   |   | 37,500 |   |
| Kenneth Galbraith (5)                                      |   |                | 33,545 |   |                      |   | 162,921 |     |   |   | 196,466                                                            |   |   | Nil |   |
| Peggy Phillips (Executive Comp and HR Committee Chair) (6) |   |                | 52,759 |   |                      |   | 210,979 |     |   |   | 263,737                                                            |   |   | Nil |   |
| Richard Henriques (7)                                      |   |                | 2,914  |   |                      |   | 0       |     |   |   | 2,914                                                              |   |   |   | 5,000 |   |

| (1) | Option-based annual awards in the amount of 7,500 were granted to the directors in 2014 at the Annual General Meeting in May. Additionally, 10,000 options were awarded to Messers Kisner, Karbe, Galbraith and Jewell. These directors were awarded 5,000 options at appointment and these grants align their total appointment awards to the more recently approved level of 15,000. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   |                                                                                                                                                                                                                      |
|--------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (2)    | Amounts shown reflect option awards vested as of April 23, 2015.                                                                                                                                                          |
|   |                                                                                                                                                                                                                      |
| (3)    | Dr. Kisner resigned from the Board effective March 4, 2015 upon the completion of the Company’s merger with OnCore.                                                                                                 |
|   |                                                                                                                                                                                                                      |
| (4)    | Mr. Jewell resigned from the Board effective March 4, 2015 upon the completion of the Company’s merger with OnCore.                                                                                                 |
|   |                                                                                                                                                                                                                      |
| (5)    | Mr. Galbraith resigned from the Board on August 22, 2014.                                                                                                                                                                 |
|   |                                                                                                                                                                                                                      |
| (6)    | Ms. Phillips joined the Board on February 12, 2014 and was awarded 15,000 options.  Ms. Phillips resigned from the Board effective March 4, 2015 upon the completion of the Company’s merger with OnCore. |
|   |                                                                                                                                                                                                                      |
| (7)    | Mr. Henriques joined the Board on December 19, 2014 and was awarded 15,000 new Board member options on March 30, 2015.                                                                                                    |

| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters |
|----------|------------------------------------------------------------------------------------------------|

| Name of Beneficial Owner                                                      |   | No. of SharesBeneficiallyOwned |       |   | Percentage |   |
|-------------------------------------------------------------------------------|--------|--------------------------------|------------|--------|------------|--------|
|  Officers and Directors                                                  |   |                           |       |   |       |   |
| Mark Murray (1)                                                               |   |                           | 515,146    |   |       |   | * |   |
| Vivek Ramaswamy (2)                                                           |   |                           | 54,915     |   |       |   | * |   |
| Herbert Conrad (3)                                                            |   |                           | 5,000      |   |       |   | * |   |
| Richard Henriques (3)                                                         |   |                           | 5,000      |   |       |   | * |   |
| Frank Karbe (4)                                                               |   |                           | 45,000     |   |       |   | * |   |
| Keith Manchester (3, 5)                                                       |   |                           | 54,915     |   |       |   | * |   |
| William Symonds                                                               |   |                           | 256,327    |   |       |   | * |   |
| Bruce Cousins (3)                                                             |   |                           | 75,000     |   |       |   | * |   |
| Mark Kowalski (3)                                                             |   |                           | 37,500     |   |       |   | * |   |
| Ian MacLachlan (6)                                                            |   |                           | 0          |   |       |   | * |   |
| Michael Abrams (7)                                                            |   |                           | 112,542    |   |       |   | * |   |
| All current directors and executive officers as a group (11 persons) (8) |   |                           | 1,161,345  |   |       |   | 2.1 | % |
|                                                                          |   |                           |       |   |       |   |   |   |
| 5% Shareholders Not Listed Above                                              |   |                           |       |   |       |   |   |   |
| Roivant Sciences, Ltd. (9)                                                    |   |                           | 16,013,540 |   |       |   | 29.5 | % |

|   | * | Less than 1.0%. |
|--------|---|-----------------|

|  (1) | Includes warrants to purchase 10,000 common shares and options exercisable within 60 days of April 23, 2015 for 440,185 common shares. |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------|

----

| (2) | Does not include 16,013,540 shares held by Roivant over which a board of three individuals including Mr. Ramaswamy shares voting and investment power. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------|

| (3) | These are options exercisable with 60 days of April 23, 2015. |
|-----|---------------------------------------------------------------|

| (4) | Includes warrants to purchase 2,500 common shares and options exercisable within 60 days of April 23, 2015 for 37,500 common shares. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------|

| (5) | Does not include 16,013,540 shares held by Roivant over which a board of three individuals including Mr. Manchester shares voting and investment power. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------|

| (6) | Dr. MacLachlan terminated his employment as Chief Technical Officer pursuant to the “good reason” termination provision in his Employment Agreement, effective December 31, 2014. The number of shares beneficial owned by Dr. MacLachlan has not been disclosed to Tekmira. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (7) | Includes warrants to purchase 2,500 common shares and options exercisable within 60 days of April 23, 2015 for 99,167 common shares. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------|

| (8) | Does not include 16,013,540 shares held by Roivant over which a board of three individuals including Messrs. Manchester and Ramaswamy are among those whom share voting and investment power. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (9) | Voting and dispositive decisions of Roivant are made collectively by Roivant’s board of directors. |
|-----|----------------------------------------------------------------------------------------------------------|

| Item 13. | Certain Relationships and Related Transactions, and Director Independence |
|----------|---------------------------------------------------------------------------|

| Item 14. | Principal Accountant Fees and Services |
|----------|----------------------------------------|

|                   |    | December 31,2014 |    |    | December 31,2013 |   |
|------------------------|--------------|-----------------------|---------|--------------|-----------------------|--------|
| Audit fees (1)         |    | $                     | 356,746 |    |             | $      | 234,146 |   |
| Audit-related fees (2) |    |                  | 0       |    |             |   | 8,253 |    |
| Tax fees (3)           |    |                  | 90,900  |    |             |   | 85,189 |    |
| Other fees             |    |                  | 0       |    |             |   | 0 |    |
| Total fees             |    | $                     | 447,646 |    |             | $      | 327,588 |    |

----

| (1) | Quarterly reviews, review of SEC listing documents and review of prospectus. |
|-----|------------------------------------------------------------------------------|
| (2) | Preliminary review of Sarbanes-Oxley internal controls                       |
| (3) | Tax compliance and tax planning.                                        |

PART IV

| Item 15. | Exhibits and Financial Statement Schedules |
|----------|--------------------------------------------|

| 1. | Financial Statements: |
|----|-----------------------|

| 2. | Financial Statement Schedules: |
|----|--------------------------------|

| 3. | Exhibits |
|----|----------|

----

|   | TEKMIRA PHARMACEUTICALS CORPORATION |
|--------|-------------------------------------|
|   |                                |   |
|   | By:                                 | /s/ Mark Murray |
|   |                                | Mark Murray |
|   |                                | President and Chief Executive Officer |

| Signatures               |   | Capacity in Which Signed                                      |
|--------------------------|--------|---------------------------------------------------------------|
|                     |   |                                                          |
|                     |   |                                                          |
| /s/ Vivek Ramaswamy      |   | Director (Chairman)                                           |
| Vivek Ramaswamy          |   |                                                          |
|                     |   |                                                          |
| /s/ Mark Murray          |   | President and Chief Executive Officer and Director            |
| Mark Murray              |   | (Principal Executive Officer)                                 |
|                     |   |                                                          |
| /s/ Bruce Cousins        |   | Executive Vice President, Finance and Chief Financial Officer |
| Bruce Cousins            |   | (Principal Financial Officer and Accounting Officer)          |
|                     |   |                                                          |
| /s/ Herbert J. Conrad    |   | Director                                                      |
| Herbert J. Conrad        |   |                                                          |
|                     |   |                                                          |
| /s/ Richard C. Henriques |   | Director                                                      |
| Richard C. Henriques     |   |                                                          |
|                     |   |                                                          |
| /s/ Frank Karbe          |   | Director                                                      |
| Frank Karbe              |   |                                                          |
|                     |   |                                                          |
| /s/ Keith Manchester     |   | Director                                                      |
| Keith Manchester         |   |                                                          |
|                     |   |                                                          |
| /s/ William T. Symonds   |   | Chief Development Officer                                     |
| William T. Symonds       |   |                                                          |

----

| ExhibitNumber |   | Description                                                                                                                                                                                                                                                                                                                                                                      |
|---------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|          |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 2.1*          |   | Subscription Agreement, between the Company and Alnylam Pharmaceuticals, Inc., dated March 28, 2008 (incorporated herein by reference to Exhibit 2.1 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                              |
|          |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 2.2*          |   | Subscription Agreement, between the Company and Roche Finance Ltd., dated March 31, 2008 (incorporated herein by reference to Exhibit 2.2 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                                         |
|          |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 2.3*          |   | Agreement and Plan of Merger and Reorganization, dated January 11, 2015, by and among Tekmira Pharmaceuticals Corporation, TKM Acquisition Corporation and OnCore Biopharma, Inc. (incorporated herein by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K/A filed with the SEC on January 26, 2015).                                               |
|          |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 3.1*          |   | Notice of Articles and Articles of the Company (incorporated herein by reference to Exhibit 1.1 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                                                                                   |
|          |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 3.2*          |   | Amendment to the Articles of the Company dated May 14, 2013 (incorporated herein by reference to Exhibit 3.2 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 28, 2014).                                                                                                                                    |
|          |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 3.3*          |   | Governance Amendment to the Articles of the Company dated March 4, 2015, (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on March 4, 2015).                                                                                                                                                             |
|          |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 3.4*          |   | Approval of Quorum Policy of the Company, adopted January 31, 2015 (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed with the SEC on February 5, 2015).                                                                                                                                                                |
|          |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 4.1*          |   | Governance Agreement between the Company and Roivant Sciences Ltd., a Bermuda exempted company, dated January 11, 2015 (incorporated herein by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K/A filed with the SEC on January 26, 2015).                                                                                                          |
|          |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 10.1†*  |   | Amendment No. 1 to the Amended and Restated Agreement, between the Company (formerly Inex Pharmaceuticals Corporation) and Hana Biosciences, Inc., effective as of May 27, 2009 (incorporated herein by reference to Exhibit 4.1 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                  |
|          |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 10.2†*  |   | Amended and Restated License Agreement, between Inex Pharmaceuticals Corporation and Hana Biosciences, Inc., dated April 30, 2007 (incorporated herein by reference to Exhibit 4.2 to the Registrant’s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).                                                          |
|          |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 10.3†*  |   | Sublicense Agreement, between Inex Pharmaceuticals Corporation and Alnylam Pharmaceuticals, Inc., dated January 8, 2007 (incorporated herein by reference to Exhibit 4.3 to the Registrant’s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).                                                                    |
|          |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 10.4†*  |   | Amended and Restated License and Collaboration Agreement, between the Company and Alnylam Pharmaceuticals, Inc., effective as of May 30, 2008 (incorporated herein by reference to Exhibit 4.4 to the Registrant’s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).                                              |
|          |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 10.5†*  |   | Amended and Restated Cross-License Agreement, between Alnylam Pharmaceuticals, Inc. and Protiva Biotherapeutics Inc., dated May 30, 2008 (incorporated herein by reference to Exhibit 4.5 to the Registrant’s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).                                                   |
|          |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 10.6†*  |   | License Agreement, between Inex Pharmaceuticals and Aradigm Corporation, dated December 8, 2004 (incorporated herein by reference to Exhibit 4.6 to the Registrant’s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).                                                                                            |
|          |   |                                                                                                                                                                                                                                                                                                                                                                             |
| 10.7†*  |   | Settlement Agreement, between Sirna Therapeutics, Inc. and Merck & Co., Inc. and Protiva Biotherapeutics Inc. and Protiva Biotherapeutics (USA), Inc., effective as of October 9, 2007 (incorporated herein by reference to Exhibit 4.7 to the Registrant’s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012). |
|          |   |                                                                                                                                                                                                                                                                                                                                                                             |

----

| 10.8†*  |   | Development, Manufacturing and Supply Agreement, between the Company and Alnylam Pharmaceuticals, Inc., dated January 2, 2009 (incorporated herein by reference to Exhibit 4.8 to the Registrant’s Amendment No. 1 to Form 20-F for the year ended December 31, 2010 filed with the SEC on January 31, 2012).                                                    |
|---------------|--------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 10.9†*# |   | Executive Employment Agreement with Ian Mortimer, dated March 26, 2008 (incorporated herein by reference to Exhibit 4.9 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                                                 |
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 10.10*#       |   | Executive Employment Agreement with Ian MacLachlan, dated May 30, 2008 (incorporated herein by reference to Exhibit 4.10 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                                                |
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 10.11*#       |   | Executive Employment Agreement with Mark Murray, dated May 30, 2008 (incorporated herein by reference to Exhibit 4.11 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                                                   |
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 10.12*#       |   | Executive Employment Agreement with Peter Lutwyche, dated January 1, 2009 (incorporated herein by reference to Exhibit 4.12 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                                             |
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 10.13*#       |   | Share Option Plan amended through May 12, 2009 (including form stock option agreements) (incorporated herein by reference to Exhibit 4.13 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                               |
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 10.14*        |   | Lease Agreement with Canada Lands Company CLC Limited dated December 15, 1997, as amended (incorporated herein by reference to Exhibit 4.14 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                             |
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 10.15*#       |   | Form of Indemnity Agreement (incorporated herein by reference to Exhibit 4.15 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                                                                                           |
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 10.16*        |   | Award Contract with USASMDC/ARSTRAT effective date July 14, 2010 (incorporated herein by reference to Exhibit 4.16 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                                                                      |
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 10.17†* |   | License Agreement between the University of British Columbia and Inex Pharmaceuticals Corporation executed on July 30, 2001 (incorporated herein by reference to Exhibit 4.17 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                           |
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 10.18†* |   | Amendment Agreement between the University of British Columbia and Inex Pharmaceuticals Corporation dated July 11, 2006 (incorporated herein by reference to Exhibit 4.18 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                               |
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 10.19†* |   | Second Amendment Agreement between the University of British Columbia and Inex Pharmaceuticals Corporation dated January 8, 2007 (incorporated herein by reference to Exhibit 4.19 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                      |
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 10.20†* |   | Consent Agreement of the University of British Columbia to Inex/Alnylam Sublicense Agreement dated January 8, 2007 (incorporated herein by reference to Exhibit 4.20 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011).                                                                    |
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 10.21†* |   | Amendment No. 2 to the Amended and Restated Agreement, between the Company (formerly Inex Pharmaceuticals Corporation) and Hana Biosciences, Inc., effective as of September 20, 2010 (incorporated herein by reference to Exhibit 4.21 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2010 filed with the SEC on June 3, 2011). |
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 10.22†* |   | License and Collaboration Agreement between the Company and Halo-Bio RNAi Therapeutics, Inc. as of August 24, 2011 (incorporated herein by reference to Exhibit 4.22 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2011 filed with the SEC on March 27, 2012).                                                                  |
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 10.23*        |   | Loan Agreement with Silicon Valley Bank dated as of December 21, 2011 (incorporated herein by reference to Exhibit 4.23 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2011 filed with the SEC on March 27, 2012).                                                                                                               |
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |
| 10.24*#       |   | Employment Agreement with Paul Brennan dated August 24, 2010 (incorporated herein by reference to Exhibit 4.24 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2011 filed with the SEC on March 27, 2012).                                                                                                                        |
|          |   |                                                                                                                                                                                                                                                                                                                                                                   |

----

| 10.25*#               |   | Tekmira 2011 Omnibus Share Compensation Plan approved by shareholders on June 22, 2011 (incorporated herein by reference to Exhibit 4.25 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2011 filed with the SEC on March 27, 2012).                                                                                                                          |
|-----------------------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.26†*         |   | Settlement Agreement and General Release, by and among Tekmira Pharmaceuticals Corporation, Protiva Biotherapeutics Inc., Alnylam Pharmaceuticals, Inc., and AlCana Technologies, Inc., dated November 12, 2012 (incorporated herein by reference to Exhibit 4.26 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2012 filed with the SEC on March 27, 2013). |
| 10.27†*         |   | Cross-License Agreement by and among Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corporation and Protiva Biotherapeutics Inc., dated November 12, 2012(incorporated herein by reference to Exhibit 4.27 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2012 filed with the SEC on March 27, 2013).                                                |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.28†*         |   | License Agreement by and among Protiva Biotherapeutics Inc. and Marina Biotech, Inc. dated November 28, 2012 (incorporated herein by reference to Exhibit 4.28 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2012 filed with the SEC on March 27, 2013).                                                                                                    |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.29*#               |   | Employment Agreement with Diane Gardiner dated March 1, 2013 (incorporated herein by reference to Exhibit 4.29 to the Registrant’s Annual Report on Form 20-F for the year ended December 31, 2012 filed with the SEC on March 27, 2013).                                                                                                                                                    |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.30*#               |   | Employment Agreement with Mark Kowalski dated August 12, 2013 (incorporated herein by reference to Exhibit 10.30 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 28, 2014).                                                                                                                                                  |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.31*#               |   | Employment Agreement with Bruce Cousins dated October 7, 2013 (incorporated herein by reference to Exhibit 10.31 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 28, 2014).                                                                                                                                                  |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.32†*         |   | Services Agreement by and among Protiva Biotherapeutics Inc., Protiva Agricultural Development Company Inc. and Monsanto Company dated January 12, 2014 (incorporated herein by reference to Exhibit 10.32 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 28, 2014).                                                        |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.33†*         |   | Option Agreement by and among Tekmira Pharmaceuticals Corporation, Protiva Biotherapeutics Inc., Protiva Agricultural Development Company Inc. and Monsanto Canada Inc. dated January 12, 2014 (incorporated herein by reference to Exhibit 10.33 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 28, 2014).                 |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.34†*         |   | License and Services Agreement by and among Protiva Biotherapeutics Inc., Protiva Agricultural Development Company Inc. and Tekmira Pharmaceuticals Corporation dated January 12, 2014 (incorporated herein by reference to Exhibit 10.34 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2013 filed with the SEC on March 28, 2014).                         |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.35*                |   | Forms of Lock-Up Agreement (incorporated herein by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K/A filed with the SEC on January 26, 2015).                                                                                                                                                                                                                        |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.36*                |   | Form of Registration Rights Agreement (incorporated herein by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K/A filed with the SEC on January 26, 2015).                                                                                                                                                                                                             |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.37*                |   | Form of Standstill Agreement (incorporated herein by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K/A filed with the SEC on January 26, 2015).                                                                                                                                                                                                                      |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.38*                |   | Form of Representation Letter (incorporated herein by reference to Exhibit 2.1 to the Registrant’s Current Report on Form 8-K/A filed with the SEC on January 26, 2015).                                                                                                                                                                                                                     |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.39*#               |   | Executive Employment Agreement with Michael Abrams, dated November 14, 2013                                                                                                                                                                                                                                                                                                                        |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.40*#               |   | Executive Employment Agreement with Kirk Rosemark, dated December 8, 2014                                                                                                                                                                                                                                                                                                                          |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.41*††  |   | License Agreement, between Tekmira Pharmaceuticals and Protiva Biotherapeutics and Dicerna Pharmaceuticals dated November 16, 2014                                                                                                                                                                                                                                                            |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.42**†† |   | Manufacturing and Clinical Trial Agreement between Tekmira Pharmaceuticals and Protiva Biotherapeutics and the Chancellor Masters and Scholars of the University of Oxford, dated December 18, 2014                                                                                                                                                                                                |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |
| 10.43*                |   | Modification Contract P0001, dated July 19, 2010, to Award Contract, dated July 14, 2010 (Exhibit 10.16)                                                                                                                                                                                                                                                                                           |
|                  |   |                                                                                                                                                                                                                                                                                                                                                                                               |

----

| 10.44*                |   | Modification Contract P0002, dated April 15, 2011, to Award Contract, dated July 14, 2010 (Exhibit 10.16)                |
|-----------------------|--------|--------------------------------------------------------------------------------------------------------------------------|
|                  |   |                                                                                                                     |
| 10.45*                |   | Modification Contract P0003, dated June 13, 2011, to Award Contract, dated July 14, 2010 (Exhibit 10.16)                 |
|                  |   |                                                                                                                     |
| 10.46*††  |   | Modification Contract P0004, dated October 3, 2011, to Award Contract, dated July 14, 2010 (Exhibit 10.16)               |
|                  |   |                                                                                                                     |
| 10.47*                |   | Modification Contract P0005, dated December 2, 2011, to Award Contract, dated July 14, 2010 (Exhibit 10.16)              |
|                  |   |                                                                                                                     |
| 10.48*                |   | Modification Contract P0006, dated January 25, 2012, to Award Contract, dated July 14, 2010 (Exhibit 10.16)              |
|                  |   |                                                                                                                     |
| 10.49*††  |   | Modification Contract P0007, dated March 5, 2012, to Award Contract, dated July 14, 2010 (Exhibit 10.16)                 |
|                  |   |                                                                                                                     |
| 10.50*                |   | Modification Contract P0008, dated April 23, 2012, to Award Contract, dated July 14, 2010 (Exhibit 10.16)                |
|                  |   |                                                                                                                     |
| 10.51*                |   | Modification Contract P0009, dated June 29, 2012, to Award Contract, dated July 14, 2010 (Exhibit 10.16)                 |
|                  |   |                                                                                                                     |
| 10.52*                |   | Modification Contract P00010, dated July 16, 2012, to Award Contract, dated July 14, 2010 (Exhibit 10.16)                |
|                  |   |                                                                                                                     |
| 10.53*                |   | Modification Contract P00011, dated July 25, 2012, to Award Contract, dated July 14, 2010 (Exhibit 10.16)                |
|                  |   |                                                                                                                     |
| 10.54*††  |   | Modification Contract P00012, dated August 2, 2012, to Award Contract, dated July 14, 2010 (Exhibit 10.16)               |
|                  |   |                                                                                                                     |
| 10.55*                |   | Modification Contract P00013, dated August 27, 2012, to Award Contract, dated July 14, 2010 (Exhibit 10.16)              |
|                  |   |                                                                                                                     |
| 10.56 *               |   | Modification Contract P00014, dated August 31, 2012, to Award Contract, dated July 14, 2010 (Exhibit 10.16)              |
|                  |   |                                                                                                                     |
| 10.57*                |   | Modification Contract P00015, dated October 1, 2012, to Award Contract, dated July 14, 2010 (Exhibit 10.16)              |
|                  |   |                                                                                                                     |
| 10.58*                |   | Modification Contract P00016, dated October  2, 2012, to Award Contract, dated July 14, 2010 (Exhibit 10.16)   |
|                  |   |                                                                                                                     |
| 10.59*                |   | Modification Contract P00017, dated October 19, 2012, to Award Contract, dated July 14, 2010 (Exhibit 10.16)             |
|                  |   |                                                                                                                     |
| 10.60*                |   | Modification Contract P00018, dated December 31, 2012, to Award Contract, dated July 14, 2010 (Exhibit 10.16)            |
|                  |   |                                                                                                                     |
| 10.61*                |   | Modification Contract P00019, dated January 23, 2013, to Award Contract, dated July 14, 2010 (Exhibit 10.16)             |
|                  |   |                                                                                                                     |
| 10.62 *               |   | Modification Contract P00020, dated February 19, 2013, to Award Contract, dated July 14, 2010 (Exhibit 10.16)            |
|                  |   |                                                                                                                     |
| 10.63 *               |   | Modification Contract P00021, dated March 29, 2013, to Award Contract, dated July 14, 2010 (Exhibit 10.16)               |
|                  |   |                                                                                                                     |
| 10.64*††  |   | Modification Contract P00022, dated April 30, 2013, to Award Contract, dated July 14, 2010 (Exhibit 10.16)               |
|                  |   |                                                                                                                     |
| 10.65*††  |   | Modification Contract P00023, dated May 21, 2013, to Award Contract, dated July 14, 2010 (Exhibit 10.16)                 |
|                  |   |                                                                                                                     |
| 10.66 *               |   | Modification Contract P00024, dated June 19, 2013, to Award Contract, dated July 14, 2010 (Exhibit 10.16)                |
|                  |   |                                                                                                                     |
| 10.67*††  |   | Modification Contract P00025, dated April 22, 2014, to Award Contract, dated July 14, 2010 (Exhibit 10.16)               |
|                  |   |                                                                                                                     |
| 10.68*††  |   | Modification Contract P00026, dated July 25, 2014, to Award Contract, dated July 14, 2010 (Exhibit 10.16)                |
|                  |   |                                                                                                                     |
| 10.69*                |   | Modification Contract P00027, dated July 25,  2014, to Award Contract, dated July 14, 2010 (Exhibit 10.16)     |
|                  |   |                                                                                                                     |
| 10.70 *†† |   | Modification Contract P00028, dated September 5, 2014, to Award Contract, dated July 14, 2010 (Exhibit 10.16)            |
|                  |   |                                                                                                                     |
| 10.71 *               |   | Modification Contract P00029, dated September 30, 2014, to Award Contract, dated July 14, 2010 (Exhibit 10.16)           |
|                  |   |                                                                                                                     |
| 10.72*††  |   | Modification Contract P00030, dated October 31, 2014, to Award Contract, dated July 14, 2010 (Exhibit 10.16)             |
|                  |   |                                                                                                                     |
| 10.73*                |   | Modification Contract P00031, dated  November 17, 2014, to Award Contract, dated July 14, 2010 (Exhibit 10.16) |
|                  |   |                                                                                                                     |

----

| 10.74*†† |   | Modification Contract P00032, dated  March 4, 2015, to Award Contract, dated July 14, 2010 (Exhibit 10.16)                                                                    |
|----------------------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                 |   |                                                                                                                                                                                    |
| 10.75*†† |   | Modification Contract P00033, dated  March 4, 2015,  to Award Contract, dated July 14, 2010 (Exhibit 10.16)                                                         |
|                 |   |                                                                                                                                                                                    |
| 10.76*               |   | Underwriting Agreement for 3,750,000 Common Shares with Stifel, Nicolaus & Company, dated October 17, 2013                                                                          |
|                 |   |                                                                                                                                                                                    |
| 10.77*               |   | Underwriting Agreement for 2,125,000 Common Shares with Leerink Partners LLC, dated March 14, 2014                                                                                      |
|                 |   |                                                                                                                                                                                    |
| 21.1*                |   | List of Subsidiaries                                                                                                                                                                    |
|                 |   |                                                                                                                                                                                    |
| 23.1*                |   | Consent of KPMG LLP, an Independent Registered Public Accounting Firm                                                                                                                   |
|                 |   |                                                                                                                                                                                    |
| 31.1**               |   | Certification of Chief Executive Officer pursuant to Rule 13a-14 or 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|                 |   |                                                                                                                                                                                    |
| 31.2**               |   | Certification of Chief Financial Officer pursuant to Rule 13a-14 or 15d-14 of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 |
|                 |   |                                                                                                                                                                                    |
| 32.1**               |   | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                      |
|                 |   |                                                                                                                                                                                    |
| 32.2**               |   | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                      |
|                 |   |                                                                                                                                                                                    |
| 101.INS*             |   | XBRL Instance Document                                                                                                                                                                  |
| 101.SCH*             |   | XBRL Taxonomy Extension Schema Document                                                                                                                                                 |
| 101.CAL*             |   | XBRL Taxonomy Extension Calculation Linkbase Document                                                                                                                                   |
| 101.DEF*             |   | XBRL Taxonomy Extension Definition Linkbase Document                                                                                                                                    |
| 101.LAB*             |   | XBRL Taxonomy Extension Label Linkbase Document                                                                                                                                         |
| 101.PRE*             |   | XBRL Taxonomy Extension Presentation Linkbase Document                                                                                                                                  |

| ***             | Previously filedFiled herewith                                                                     |
|-----------------|----------------------------------------------------------------------------------------------------|
| †         | Confidential treatment granted as to portions of this exhibit.                                     |
| ††# | Confidential treatment has been requested as to portions of this exhibit.Management Contract  |

----